Test Details
Methodology
Immunochemiluminometric assay (ICMA)
Result Turnaround Time
Within 1 day
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Use
Manage patients with metastatic carcinoma of the breast
Special Instructions
Values obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy. This procedure does not provide serial monitoring; it is intended for one-time use only. If serial monitoring is required, please order the serial monitoring test (480293).
Limitations
For the quantitative determination of CA 27.29 antigen in serum of patients previously treated for stage II or stage III breast cancer. Serial testing for CA 27.29 antigen in patients who are clinically free of disease should be used in conjunction with other clinical methods for the early detection of recurrence.
References
Custom Additional Information
CA 27.29 is a highly polymorphic glycoprotein belonging to the mucin family and is the product of the muc-1 gene. It is most useful using serial measurements to monitor both the course of disease and response to therapy because the direct correlation of changing levels of CA 27.29 with clinical status. In patients with known metastases, a reduction in levels of this marker indicates a good response to treatment while increasing levels indicate resistance to therapy and progressive disease and justify further clinical evaluation and regular monitoring. It has also recently been shown that an elevation of CA 27.29 levels above the upper limit of normal in patients with no clinical evidence of disease is an early indicator of recurrence. An elevated serum CA 27.29 level in patients in remission of stage II or III breast cancer provided a positive predictive value of 83.3% for recurrent disease, with an average lead time of 5.3 months before recurrence was clinically established.
Specimen Requirements
Specimen
Serum
Volume
1 mL
Minimum Volume
0.3 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube or gel-barrier tube
Collection Instructions
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Stability Requirements
Temperature | Period |
---|---|
Refrigerated | 5 days |
Frozen | >1 month |
Reference Range
0−38.6 units/mL
Storage Instructions
Refrigerate.
Causes for Rejection
Plasma other than EDTA plasma
LOINC® Map
Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
---|---|---|---|---|---|---|
140293 | CA 27.29 | 17842-6 | 142134 | CA 27.29 | U/mL | 17842-6 |
Order Code | 140293 | |||||
Order Code Name | CA 27.29 | |||||
Order Loinc | 17842-6 | |||||
Result Code | 142134 | |||||
Result Code Name | CA 27.29 | |||||
UofM | U/mL | |||||
Result LOINC | 17842-6 |